Auckland, New Zealand

Hemanth Pemmaraju

This inventor holds 2 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: Fisher & Paykel Healthcare Limited. Active years: 2024-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2024-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Mind of Hemanth Pemmaraju

Introduction: Hemanth Pemmaraju, based in Auckland, New Zealand, has made a significant impact in the field of healthcare technology. With a focus on respiratory devices, he has contributed to the development of critical innovations that enhance patient care.

Latest Patents: Hemanth holds a patent for a "Respiratory Conduit with Connector," which showcases his commitment to improving respiratory health solutions. This invention aims to provide a more efficient and user-friendly interface for patients and healthcare providers alike.

Career Highlights: Currently employed at Fisher & Paykel Healthcare Limited, Hemanth has played an essential role in advancing the company's mission to develop innovative healthcare solutions. His work is instrumental in ensuring that the company remains at the forefront of medical technology.

Collaborations: Collaborating with talented professionals like Brad Michael Howarth and Pearl Mariah D'Souza, Hemanth has been part of a dynamic team that fosters creative problem-solving and innovation. Together, they work towards creating products that cater to the diverse needs of patients.

Conclusion: Hemanth Pemmaraju's contributions to the field of respiratory health through his patent and collaborative efforts highlight the importance of innovation in healthcare. His work at Fisher & Paykel Healthcare Limited continues to inspire advancements that ultimately improve patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…